Iovance Biotherapeutics, Inc. (IOVA) Q3 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Welcome to the Iovance Biotherapeutics third quarter and year-to-date 2025 conference call. My name is Daniel, and I will be your operator for today's call. At this time, all participants are in a listen-only mode. Later, we will conduct a question and answer session. Please note that this conference call is being recorded. I will now turn the call over to Sarah Pellegrino, Senior Vice President in Best Relations, and Corporate Communications at Iovance. Sarah, you may begin. Thank you, Operator. Good morning, and welcome to the Iovance webcast to discuss our business achievements, pipeline milestones, and third quarter 2025 results. Members of our executive leadership team speaking on today's call include Dr. Fred Vose, Interim CEO and President, Coraline Roche, Chief Financial Officer, Dan Kirby, Chief Commercial Officer, Dr. Igor Balinski, Chief Operating Officer, and Dr. Frederick Finkenstein, Chief Medical Officer. During the question and answer session, we will also welcome Drs. Raj Puri and Mark Suray from our Regulatory Affairs Executive Leadership Team, and Dr. Brian Gassman, Executive Vice President of Translational Medicine and Research. This morning, we issued a press release that is available on our corporate website at iobance.com. I would like to remind everyone that this conference call will include forward-looking statements regarding Iovance's goals, business focus, business plans and transactions, revenue and revenue guidance, commercial activities, clinical trials and results, regulatory approvals and interaction, plans and strategies, research and preclinical activities, potential future applications of our technologies, manufacturing capabilities, regulatory feedback and guidance, payer interaction, restructuring, licenses and collaborations, ca...